Emergent Biosolutions, Inc. (EBS)
NYSE: EBS · Pharmaceutical Preparations · Gaithersburg, MD · filing with the SEC since 2006
Grade4.6
◀ Past 4.6● Present 5.4▶ Future 3.5
Who owns Emergent Biosolutions, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 9% of Common Stock, as its SCHEDULE 13G/A filed Jul 28, 2026 says.
Directors and officers
17
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 28, 2026 · Common Stock · 7.3% in Jul 17, 2025
American Century Investment Management, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock
Dimensional Fund Advisors LP
SCHEDULE 13G · filed Apr 9, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 9, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock · reported falling below 5%, from 5.04% in Apr 29, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 6.76% in Jan 30, 2026
What EBS reports owning in othersstakes of 5% or more, and other ties
19 subsidiaries in 8 countries, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
15sales
0purchases
11sales on a scheduled plan
6people selling
$1.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 7, 2025 to Oct 7, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 7, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Degolyer Donald W | director | 4 | $400,000 | 3 | 0 | $0 |
| Glessner Coleen | EVP, Quality & Ethics, and CPL | 1 | $300,000 | 0 | 0 | $0 |
| Richard Ronald | director | 2 | $300,000 | 0 | 0 | $0 |
| Dayal Sujata Tyagi | director | 3 | $200,000 | 2 | 0 | $0 |
| Williams Paul Anthony | SVP, Products Business | 3 | $100,000 | 3 | 0 | $0 |
| Katkin Keith | director | 1 | $100,000 | 1 | 0 | $0 |
| Zoon Kathryn C | director | 2 | $100,000 | 2 | 0 | $0 |